Core Viewpoint - The legal opinion issued by Shanghai Tongli Law Firm confirms that Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is legally qualified to implement its 2025 Restricted Stock Incentive Plan, having complied with relevant laws and regulations [4][19]. Group 1: Implementation Conditions - Hubei Hongyuan holds a valid business license issued by the Huanggang Market Supervision Administration, confirming its legal existence as a joint-stock limited company [4]. - The company has received approval from the China Securities Regulatory Commission for its initial public offering, issuing 47.2572 million shares at a par value of 1 RMB per share, which began trading on March 20, 2023 [5]. - The company has no disqualifying conditions under the regulations that would prevent it from implementing the stock incentive plan [6]. Group 2: Legal Compliance of the Incentive Plan - The draft of the 2025 Restricted Stock Incentive Plan was approved by the company's board of directors, outlining its objectives, management structure, and eligibility criteria for participants [6][7]. - The plan includes detailed provisions on the number of shares to be granted, the criteria for vesting, and the rights and obligations of both the company and the incentive recipients [7][8]. Group 3: Procedures for Implementation - The company has followed necessary procedures, including the review and approval of the incentive plan by the board and the supervisory committee, and must disclose relevant information to shareholders [10][11]. - The plan requires approval from at least two-thirds of the voting rights held by non-related shareholders at the shareholders' meeting [19]. Group 4: Impact on Company and Shareholders - The incentive plan aims to enhance corporate governance, attract and retain key personnel, and align the interests of shareholders and management, thereby promoting sustainable development [19]. - The plan will not involve financial assistance to the incentive recipients, ensuring compliance with relevant regulations [19][16]. Group 5: Conclusion - The legal opinion concludes that the draft incentive plan complies with the Company Law, Securities Law, and other relevant regulations, and has met the necessary procedural and disclosure requirements [19][20].
宏源药业: 上海市通力律师事务所关于湖北省宏源药业科技股份有限公司2025年限制性股票激励计划的法律意见书